NCT05543174已完成3 期
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome
Takeda8 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2023年1月16日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 7
- 试验地点
- 8
- 主要终点
- Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22
研究概览
简要总结
The main aim of the study is to check if TAK-625 improves symptoms of Alagille Syndrome (ALGS), side effect from the study treatment or TAK-625, and how much TAK-625 stays in their blood over time. This will help the study sponsor (Takeda) to work out the best dose to give people in the future.
The participants will be treated with TAK-625 for up to the end of study (about 34 months).
Participants will visit their study clinic 9 times from the start of study. After 9 times visits, participants will visit their study clinic every 12 weeks up to the end of study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Month 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The participant is Japanese male or female with a body weight >=3.0 kilograms (kg) and who is >=1 month of age at the time of informed consent.
- •The participant is diagnosed with ALGS.
- •The participant has one or more of the following evidences of cholestasis:
- •Total serum bile acid (sBA) >3^ upper limit of the normal range (ULN) for age.
- •Direct bilirubin (conjugated) >1 mg/dL.
- •Lipid soluble vitamin (LSV) deficiency otherwise unexplainable.
- •Gamma-glutamyl transferase (GGT) >3^ ULN for age.
- •Intractable pruritus explainable only by liver disease.
- •The participant is expected to have a consistent caregiver(s) for the duration of the study.
- •The participant has an access to phone for scheduled calls from study site.
- •Both a caregiver and participant above the age of assent are capable of reading and understanding the questionnaires.
- •Caregivers (and age-appropriate participants) must be willing and able to use an eDiary device during the study.
- •Caregivers (and age-appropriate participants) must complete at least 10 eDiary reports (morning or evening) during each of 2 consecutive weeks of the screening period (maximum possible reports=14 per week), even if the participant is an adult (over 18 years old).
- •Average daily score >2 on the ItchRO questionnaire (maximum possible daily score of 4) for 2 consecutive weeks in the screening period, prior to dosing. A daily score is the higher of the scores for the morning and evening ItchRO. The average daily score is the sum of all daily scores divided by the number of days the ItchRO was completed. Since it is difficult to evaluate pruritus in infants, participants <12 months of age at screening whose pruritus is unavoidably difficult to be evaluated are not necessarily required to meet the above score.
排除标准
- •The participant has chronic diarrhea requiring ongoing intravenous (IV) fluid or nutritional intervention.
- •The participant has a previous history of surgical interruption of the enterohepatic circulation.
- •The participant has a previous liver transplant.
- •The participant decompensated cirrhosis (ALT >15^ ULN, international normalized ratio [INR] >1.5 [unresponsive to vitamin K therapy], albumin <3.0 g/dL, history or presence of clinically significant ascites, variceal hemorrhage, and/or encephalopathy).
- •The participant has a history or presence of other concomitant liver disease.
- •The participant has a history or presence of any other disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs, including bile salt metabolism in the intestine (eg, inflammatory bowel disease).
- •The participant has a history or presence of gallstones or kidney stones.
- •The participant has a possible malignant liver mass in imaging, including screening ultrasound.
- •The participant has cancers, except for in situ carcinoma, or cancers treated at least 5 years prior to screening with no evidence of recurrence.
- •The participant has received bile acid/lipid binding resins or IBAT inhibitors within 28 days prior to screening and throughout the trial.
- •The participant who has received sodium phenylbutyrate for less than 6 months at the initiation of screening.
研究组 & 干预措施
TAK-625
Experimental
TAK-625 200 mcg per kilogram, orally, once daily for 1 week. After that, TAK-625 400 mcg per kilogram, orally, once daily after Week 1.
干预措施: TAK-625 (Drug)
结局指标
主要结局
Change in Fasting Serum Bile Acid (sBA) Levels From Week 18 to Week 22
时间窗: From Week 18 to Week 22
Change in fasting sBA levels from Week 18 to 22 was reported. Change was calculated as: observed value at Week 22- observed value at Week 18.
次要结局
- Change in Fasting sBA Levels From Baseline to Week 18(Baseline to Week 18)
- Change in Weekly Average Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18(Baseline to Week 18)
- Change in Weekly Average Morning Severity of Pruritus Measured by Itch Reported Outcome (ItchRO) (Observer Instrument [Obs]) From Baseline to Week 18(Baseline to Week 18)
- Change in Weekly Average Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22(From Week 18 to Week 22)
- Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Obs) From Week 18 to Week 22(From Week 18 to Week 22)
- Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18(Baseline to Week 18)
- Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Baseline to Week 18(Baseline to Week 18)
- Change in Alanine Aminotransferase (ALT) and Alkaline Phosphatase (ALP) Levels From Baseline to Week 18(Baseline to Week 18)
- Change in Bilirubin (Total and Direct) Levels From Baseline to Week 18(Baseline to Week 18)
- Change in Weekly Average Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22(From Week 18 to 22)
- Change in Weekly Average Morning Severity of Pruritus Measured by ItchRO (Pt) From Week 18 to Week 22(From Week 18 to 22)
- Change in ALT and ALP Levels From Week 18 to 22(From Week 18 to 22)
- Change in Bilirubin (Total and Direct) Levels From Week 18 to 22(From Week 18 to 22)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
3 期
A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC)Progressive Familial Intrahepatic Cholestasis (PFIC)NCT05543187Takeda5
进行中（未招募）
3 期
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque PsoriasisPlaque PsoriasisNCT06550076Takeda2,099
已完成
1 期
Safety, Tolerability and Pharmacokinetic Study of Multiple Rising Doses of TAK- 063 in Participants With Stable Schizophrenia and Healthy ParticipantsSchizophreniaNCT01879722Takeda77
已完成
3 期
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisErythrodermic PsoriasisGeneralized Pustular PsoriasisNCT06323356Takeda18
已完成
1 期
A Study to Evaluate Central Nervous System (CNS) Pharmacodynamic Activity of TAK-653 in Healthy Participants Using Transcranial Magnetic Stimulation (TMS)Healthy VolunteersNCT03792672Neurocrine Biosciences24